TY  - GEN
AU  - Isaacs,Claudine
AU  - Herbolsheimer,Pia
AU  - Liu,Minetta C
AU  - Wilkinson,Mary
AU  - Ottaviano,Yvonne
AU  - Chung,Gina G
AU  - Warren,Robert
AU  - Eng-Wong,Jennifer
AU  - Cohen,Philip
AU  - Smith,Karen L
AU  - Creswell,Karen
AU  - Novielli,Antonella
AU  - Slack,Rebecca
TI  - Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer
SN  - 1573-7217
PY  - 2011///0321
KW  - Adult
KW  - Aged
KW  - Anastrozole
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Aromatase Inhibitors
KW  - administration & dosage
KW  - Benzenesulfonates
KW  - Breast Neoplasms
KW  - chemistry
KW  - Disease-Free Survival
KW  - Drug Resistance, Neoplasm
KW  - Endothelial Cells
KW  - drug effects
KW  - Female
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Middle Aged
KW  - Niacinamide
KW  - analogs & derivatives
KW  - Nitriles
KW  - Phenylurea Compounds
KW  - Protein Kinase Inhibitors
KW  - Pyridines
KW  - Receptors, Estrogen
KW  - analysis
KW  - Receptors, Progesterone
KW  - Sorafenib
KW  - Stem Cells
KW  - Time Factors
KW  - Treatment Outcome
KW  - Triazoles
KW  - United States
N1  - Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1007/s10549-010-1226-z
ER  -